TBI Followed by GVHD Prophylaxis Decreases the Incidence of GVHD in Hematologic Malignancies
Myeloablative transplantation with a total body irradiation regimen followed by a graft-versus-host disease prophylaxis regimen led to a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies.
Topical Ruxolitinib Shown to be Effective and Tolerable in Cutaneous cGVHD
April 25th 2022Topical ruxolitinib has shown improved reduction of body surface area of cutaneous chronic graft-vs-host disease vs standard moisturizer vehicle cream, according to interim study results from a poster presented at the 2022 Transplantation & Cellular Therapy Meetings.
Four Baseline Characteristics Predict CR/sCR in Multiple Myeloma
Investigators have identified immunoglobulin G heavy chain, soluble B-cell maturation agent, prothrombin time and international normalized ratio, and high vector copy number in drug product as predictors for response in patients with multiple myeloma.
CAR T-cell Therapy Demonstrates Efficacy Without Increased Risk of CRS or ICANS in CNS-Involved LBCL
The CAR T-cell therapies axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel evoked responses without increased risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome in patients with primary or secondary central nervous system large B-cell lymphoma.
Axi-cel Demonstrates Durable Responses in Indolent Non-Hodgkin Lymphoma
April 25th 2022Axicabtagene ciloleucel continued to elicit high response rates and durable activity in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, according to updated findings from the phase 2 ZUMA-5 trial.
Belimumab Emerges as Potential Prophylaxis for Chronic GVHD Following Allogenic Transplant
April 24th 2022Belimumab could be a potential treatment used to prevent chronic graft-vs-host-disease in patients undergoing allogeneic hematopoietic transplantation by inhibiting BAFF and limiting the survival of aforeactive B cells.
Novel Gene Signature Found in Cutaneous Chronic GVHD Responders to Topical Ruxolitinib
April 24th 2022A differentially expressed gene profile was identified in patients with cutaneous nonsclerotic and superficially sclerotic chronic graft-vs-host-disease who responded to treatment with topical ruxolitinib.
Axi-cel Demonstrates Long-Term Survival Benefit in Relapsed/Refractory LBCL
April 24th 2022Axicabtagene ciloleucel resulted in a longer overall survival benefit in patients with relapsed or refractory large B-cell lymphoma who did not have event-free survival events at months 12 and 24 vs those who experienced events at these time points.
Dr. Walters on the Safety Profile of Beti-Cel in Pediatric Transfusion-Dependent Beta-Thalassemia
February 26th 2021Mark Walters, MD, discusses the safety profile of betibeglogene autotemcel gene therapy in pediatric patients with transfusion-dependent β-thalassemia, as reported in the phase 3 Northstar-2 and Northstar-3 trials.
Off-the-Shelf NK Immunotherapy With Chemotherapy and Transplant Shows Early Activity in B-Cell NHL
February 17, 2021 — Cord blood–derived natural killer immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant, showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma.
Itolizumab Leads to Sustained Clinical Responses in Newly Diagnosed Acute GVHD
February 16, 2021 - Itolizumab, a humanized IgG1 monoclonal antibody that modulates the activated leukocyte cell adhesion molecule pathway, represents a promising approach for the treatment of patients with newly diagnosed acute graft-versus-host disease.
Orca-T Displays GVHD Prevention, Scalability Potential, and Tolerability in Hematologic Cancers
February 11, 2021 - Treatment with the first-generation precision cell therapy Orca-T led to a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, a lack of treatment-related mortalities, while showcasing scalability potential.
Iomab-B/Transplant Causes Fewer AEs Versus Conventional Care in AML
February 11th 2021February 11, 2021 - A conditioning regimen comprised of targeted radiation with Iomab-B led to a lower incidence of sepsis as well as trends toward reduced rates of severe mucositis and febrile neutropenia versus conventional care and standard conditioning regimens in older adults with relapsed or refractory acute myeloid leukemia.
Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML
February 11, 2021 — Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia.
Beti-Cel Results in Impressive Activity in Pediatric Transfusion-Dependent Beta-Thalassemia
February 10, 2021 - Treatment with the investigative gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients less than 18 years of age with transfusion-dependent beta-thalassemia with a median average hemoglobin of 11.3 g/dL.